* Taro Pharmaceutical Industries Ltd TARO.N TARO.K is
expected
to show a rise in quarterly revenue when it reports results on
October 26 (estimated).
* The Haifa Israel-based company is expected to report a
22.0% increase in revenue to $161.023 million from $131.99
million a year ago, according to the estimate from one analyst,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Taro Pharmaceutical
Industries Ltd is for earnings of 84 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Taro
Pharmaceutical Industries Ltd is $54, above its last closing
price of $31.97.
This summary was machine generated October 24 at 11:14 GMT. All
figures in US dollars unless otherwise stated